期刊文献+

乳腺癌常用靶向治疗药物的心血管不良反应 被引量:7

Cardiovascular adverse reactions caused by commonly used drugs for targeted therapy of breast cancer
原文传递
导出
摘要 乳腺癌是女性最常见的恶性肿瘤。乳腺癌的靶向治疗越来越受到临床医师的重视,针对不同靶点的靶向治疗通常能使相应的患者从中受益。但是,由于肿瘤细胞靶向治疗药物作用的某些靶点与心血管系统的部分细胞表达的抗原相同,靶向治疗药物在杀灭肿瘤细胞的同时,亦对患者的心血管系统造成损伤,因此,靶向治疗药物的心血管不良反应值得临床医师重视。笔者综述了乳腺癌常用靶向治疗药物心血管不良反应的研究,包括心血管不良反应发生的风险及相关事件等,并强调在相关药物的治疗选择方面,需要考虑发生心血管不良反应的可能性及应对措施,进行靶向治疗时需要对风险和收益进行评估,从而选择最适合的方法,以便更好地监测和预防心血管不良事件,更好地应用靶向药物治疗。
出处 《中华乳腺病杂志(电子版)》 CAS CSCD 2018年第3期182-186,共5页 Chinese Journal of Breast Disease(Electronic Edition)
  • 相关文献

参考文献2

二级参考文献30

  • 1胡夕春,王佳蕾.曲妥珠单抗(赫赛汀)最新临床研究进展[J].临床药物治疗杂志,2004,2(6):45-51. 被引量:13
  • 2Milani A, Montemurro F, Gioeni L, et al. Role of trastuzum- ab in the management of HER2-positive metastatic breast cancer[J]. Breast cancer, 2010, 2: 93-109.
  • 3Piotrowski G, Gawor R, Stasiak A, et al. Cardiac complica- tions associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epi- dermal growth factor receptor type 2-a prospective study [J]. Arch Med Sci, 2012, 8(2): 227-235.
  • 4Babar T, Blomberg C, Hoffner E, et al. Anti-HER2 cancer therapy and cardiotoxicity[J]. Curt Pharm Des, 2014, 20 (30): 4911-9.
  • 5Aitelhaj M, Lkhouyaali S, Rais G, et al. Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: obser- vational monocentric study of about 100 patients[J]. BMC Res Notes, 2013, 6: 339.
  • 6Farolfi A, Melegari E, Aquilina Met al. Trastuzumab-in- duced cardiotoxicity in early breast cancer patients: a retro- spective study of possible risk and protective factors[J]. Heart, 2013, 99(9): 634-639.
  • 7Milano GA, Serres E, Ferrero JM, et al. Trasmzumab-in- duced cardiotoxicity:is it a personalized risk?[J]. Curr Drug Targets, 2014, 15(13): 1200-1204.
  • 8Tarantini L, Gori S, Faggiano P, et al. Adjuvant trastuzum- ab cardiotoxicity in patients over 60 years of age with ear- ly breast cancer: a multicenter cohort analysis[J]. Annals of Oncology, 2012, 23(12): 3058-3063.
  • 9Erin J, Aiello Bowles, Robert Wellman. Risk of heart fail- ure in breast cancer patients after anthracycline and trastu- zumab treatment: a retrospective cohort study[J]. Oxford Journals, 2012, 104(17): 1293-12305.
  • 10Fried G, Regev T, Moskovitz M. Trastuzumab-related car- diac events in the treatment of early breast cancer[J]. Breast Cancer Research and Treatment, 2013, 142(1): 1-7.

共引文献21

同被引文献52

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部